Video Experimental Relacionado
Updated: Jul 13, 2026
04:47
Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis
Published on: October 27, 2023
Efectos del metotrexato en pacientes con artritis reumatoide con comorbilidad cardiovascular
Lancet (London, England)
|May 23, 2000
Resumen
El metotrexato, un medicamento para la artritis reumatoide, eleva los niveles de homocisteína y aumenta el riesgo de mortalidad en pacientes con problemas cardiovasculares. Esto pone de relieve una preocupación crítica de seguridad para el manejo de pacientes con artritis reumatoide con afecciones cardíacas.
Área de la Ciencia:
- Reumatología Reumatología.
- Medicina Cardiovascular La medicina cardiovascular es una especialidad de la salud.
- Farmacología Farmacología.
Sus antecedentes:
- La artritis reumatoide (AR) es una enfermedad inflamatoria crónica.
- El metotrexato es un medicamento antirreumático común.
- La comorbilidad cardiovascular es prevalente en pacientes con AR.
Objetivo del estudio:
- Para investigar el impacto del metotrexato en la mortalidad en pacientes con artritis reumatoide con comorbilidad cardiovascular.
Principales métodos:
- Diseño del estudio de observación.
- Análisis de datos de pacientes, incluida la medicación, las comorbilidades y la mortalidad.
- Análisis estadístico para determinar los factores de riesgo.
Principales resultados:
- El uso de metotrexato se asoció con un aumento de la mortalidad.
- Los niveles elevados de homocisteína en suero pueden ser un factor contribuyente.
- El riesgo fue particularmente notable en pacientes con comorbilidad cardiovascular.
Conclusiones:
- El metotrexato puede aumentar el riesgo de mortalidad en pacientes con artritis reumatoide con enfermedad cardiovascular.
- El monitoreo de los niveles de homocisteína en estos pacientes es importante.
- Se justifica una mayor investigación sobre los mecanismos que vinculan el metotrexato, la homocisteína y los resultados cardiovasculares.
Videos de Conceptos Relacionados
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:17Aortic Regurgitation IV: Nursing Management
A nurse managing a patient with aortic regurgitation begins with a comprehensive assessment, including a review of the patient's medical history, family history, and lifestyle factors. During the cardiac examination, the nurse listens for heart sounds and checks for signs of valve abnormalities. The nurse also observes for symptoms such as dyspnea, orthopnea, and paroxysmal nocturnal dyspnea and assesses the patient's endurance and daily activity tolerance.Based on the findings, the nurse...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:20Rheumatic Heart Disease IV: Nursing Management
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...